The Josep Carreras Leukaemia Research Institute participates in an important clinical study on multiple myeloma
• Dr. Albert Oriol, a hematologist at the Catalan Institute of Oncology/Germans Trias i Pujol Hospital, and researcher at the Josep Carreras Leukaemia Research Institute, takes part in an international study to assess a promising combination of drugs in the treatment of multiple myeloma.
• Multiple myeloma is still an incurable disease, but progress made over the last ten years has led to a very considerable improvement in the range of available treatments to combat it. One of these promising drugs is called daratumumab.
• In Spain there are 40 new cases of multiple myelomaper million inhabitants each year.